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Doxycycline is a long-acting/second generation tetracycline
antibiotic, and currently is one of the most commonly pre-
scribed antibiotics in the world, used to treat a wide variety of
infectious agents including susceptible intracellular/zoonotic
pathogens [1–6].
Because doxycycline was introduced prior to an appreciation
of pharmacodynamic concepts, the optimal dosing regimen has
not been determined. This in vitro study was conducted to
determine the optimal dosing regimen for doxycycline based
upon pharmacodynamic data.
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Doxycycline was tested against selected Gram-positive patho-
gens, e.g. Staphylococcus aureus and Streptococcus pneumoniae and
Gram-negative pathogens, e.g. P. multocida and E. coli. Time-kill
studies were performed with each of these organisms at various
serum concentrations representing two, four, eight, and 16 times
the MIC of each test organism. The growth of the organisms was
assessed by colony counts at various time points during a 24 h
period to determine if doxycycline kills susceptible organisms
by concentration or time-dependent kinetics. Studies were also
carried to determine the PAE of doxycycline.
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Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC
25923), Pasteurella multocida, and Streptococcus pneumoniae
(ATCC 49619) were used as the test bacteria.
Inocula were prepared using Mueller–Hinton broth for E.
coli, and Mueller Hinton broth with 1% Fildes and 20 mm NaCl
for S. aureus and P. multocida, and cation-adjusted Mueller-
Hinton broth (CAMH) with 5% lysed horse blood (LHB) for
S. pneumoniae. The inocula were incubated at 37 °C with shak-
ing until turbid (3–4 h). The turbidity was adjusted to 0.5
McFarland standard (representing a concentration of 108
CFU/mL). A portion of the 0.5 McFarland standard was diluted
1 : 100 (106 CFU/mL) with broth. One milliliter of this
dilution was added to each cuvette well containing varying
concentrations of doxycycline (0.02–1.6 mg/L). One cuvette
well containing no antibiotic was used as a control for organism
viability. The cuvettes were placed in an agitator and incubated
at 37 °C for 24 h. The lowest concentration of doxycycline that
inhibited visible growth for 24 h was recorded as the minimum
inhibitory concentration (MIC) of the organism. The MIC for
E. coli (ATCC 25922) was 1.5 mg/L, for Staphylococcus aureus
(25923) 0.28 mg/L, for P. multocida 0.09 mg/L, and for Strep-
tococcus pneumoniae (ATCC 49619) 0.16 mg/L [7,8].
The post-antibiotic effect (PAE) was determined for doxy-
cycline for each of the organisms mentioned above by the
method described by Craig and Gudmundsson [9]. An over-
night growth of E. coli, Staphylococcus aureus, P. multocida, and
Streptococcus pneumoniae was diluted into fresh broth, appropriate
for each organism, to 106 CFU/mL and then incubated on a
shaker at 37 °C for 3–4 h until logarithmic growth phase was
achieved. At the end of this period, the inoculum size was
determined and each tube containing the test organisms was
then exposed to doxycycline at twice the MIC, four times the
MIC, and 16 times the MIC for 1 h at 37 °C in a shaker. A
suspension of each organism that was not exposed to antibiotics
was used as control and was subjected to the same procedures
described. Antibiotics were introduced at time zero of anti-
microbial exposure. At the end of the exposure period the
supernatant was decanted after centrifugation at 1200 g for
10 min and the pellet was re-suspended in fresh broth. The
same procedure was repeated and after removal all tubes were
again incubated at 37 °C.
Counts of CFU/mL were performed on all cultures at time
zero, before and after washing and every hour thereafter until
6 h and the counts of CFU/mL were graphed. The PAE was
determined by the following equation: PAE = T – C where T
is the time required for the counts of CFU/mL in the test
culture to increased one 1 log10 above the count observed
immediately after antibiotic removal and C is the time required
for the count of CFU/mL in an untreated control culture to
increase 1 log10 above the count observed immediately after
completion of the same procedure used on the test culture for
antibiotic removal [9,10]
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The data indicate that at low concentrations of doxycycline,
i.e. at 2 to 4 times the MIC, inhibition of the organisms tested
occurs in a time-dependent fashion. However, at higher con-
centrations, i.e. 8 to 16 times the MICs of the organisms,
doxycycline exhibits concentration-dependent killing (Figure 1).
The PAE of doxycycline was demonstrated for the Gram-
positive and Gram-negative organisms tested. Doxycycline’s
post-antibiotic effect is concentration dependent. The post-
antibiotic effect for the Gram-positive and Gram-negative
organisms tested is approximately equal (Figure 2).
For serious infections such as Legionnaire’s disease, doxy-
cycline therapy should be initiated with a 72 h loading regimen
because of its high lipid solubility. A dose of 200 mg intra-
venously every 12 h is the preferred regimen to provide rapid
and high serum/tissue concentration of doxycycline. If doxy-
cycline is administered as a 100 mg intravenous dose every 12 h
then 4–5 days of therapy are needed before the patient is fully
saturated and a therapeutic effect can be expected. As with
other antibiotics, a period of four to five serum half-lives is
required before steady-state kinetics are achieved. Since the
serum half-life (t1/2) of doxycycline is 22 h, it should be apparent
that an initial 72 h loading regimen is required if a rapid thera-
peutic effect is desired in seriously ill patients [1,6]
The post-antibiotic effect of doxycycline differs from other
tetracyclines, but is not clinically relevant since therapeutic
serum levels are present over the entire duration of the dosing
period [7,12,13]. Our data suggest that doxycycline may be
administered on a 12 h or 24 h dosing basis when a 400 mg
(intravenous/oral) daily dose is used. Clinically, with moderate
to severe infections, it is important to use a doxycycline loading
regimen to rapidly achieve high blood and tissue concen-
trations. Non-loading dose regimens should be used for patients
who are not seriously ill. In terms of pharmacoeconomics, it is
most cost effective to administer doxycycline intravenously on
a once-daily basis because there is a hospital charge for each
intravenously administered dose. A 24 h-dosing regimen elim-
inates the additional administration cost of a 12 h-dosing regi-
men.
Doxycycline is the most commonly used tetracycline for the
treatment of a wide variety of infectious diseases. Introduced
decades before pharmacodynamic considerations were appreci-
ated, the dosing of doxycycline has been based on phar-
macokinetic parameters. This is the first pharmacodynamic
study of doxycycline.
Doxycycline exhibits time-dependent killing at two to four
times the MIC, but dose-dependent killing at eight to 16 times
the MIC of the organisms tested. Optimal dose-dependent
killing may be achieved using 200 mg (intravenous/oral) every
12 h or 400 mg (intravenous/oral) every 24 h. In mild to mod-
erate infections, time-dependent killing is sufficiently effective
and doxycycline may be dosed as 100 mg (intravenous/oral)
every 12 h or 200 mg (intravenous/oral) every 24 h.
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Figure 1 Doxycycline kill curves: (a) Staphylococcus aureus; (b) Streptococcus pneumoniae; (c) Pasteurella multocida; (d) Escherichia coli.
Figure 2 Doxycycline post-antibiotic effects (PAEs) (a) Staphylococcus aureus; (b) Streptococcus pneumoniae; (c) Pasteurella maltophilia; (d)
Escherichia coli.
Doxycycline exerts a PAE which is dose dependent and
varies between 2.1 and 4.2 h.
In conclusion, doxycycline kills by time-dependent kinetics
at low serum concentrations, but optimally at high serum con-
centrations by concentration-dependent kinetics. Non-criti-
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cally ill patients may be treated effectively using either 100 mg
(intravenous/oral) every 12 h or 200 mg (intravenous/oral)
every 24 h regimen. Based on our in vitro pharmacodynamic
data, a high-dose doxycycline regimen, i.e. 200 mg every 12 h
or 400 mg every 24 h regimen should provide for optimal con-
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centration-dependent killing. The PAE of doxycycline is clini-
cally unimportant since adequate serum concentrations are
maintained for the duration of the dosing interval if given on a
12 h or 24 h basis.
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Gastroenteritis caused by nontyphoidal salmonellae is a com-
mon entity, usually self-limiting and not requiring antibiotic
treatment. However, in immunocompromised patients or in
invasive infections rapid and efficacious treatment is required.
The increase in resistance displayed by this pathogen to the
antibiotics classically used in salmonellosis (ampicillin, cotri-
moxazol, chloramphenicol, etc.) has caused ciprofloxacin to be
considered the antibiotic of choice in the treatment of invasive
salmonellosis.
Resistance to fluoroquinolones in non-typhoidal sal-
monellae is infrequent, with very few cases reported in the
literature [1–5]. However, there are reports of clinical failures
in the treatment with ciprofloxacin of strains that, although
susceptible, have increased MICs for this antibiotic [6,7].
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The National Committee for Clinical Laboratory Standards
(NCCLS) [8] considers as susceptible to ciprofloxacin all those
strains of Salmonella enterica which have MICs  1 mg/L.
According to this criterion, ciprofloxacin resistance in the vari-
ous species of S. enterica is exceptional [1–4]. However, there
are authors who recommend adjusting the cutoff points to
consider susceptible only those strains with MICs0.125 mg/L
[1,9].
Resistance to nalidixic acid in Salmonella enterica, although
of slight clinical importance given its infrequent use in the
treatment of salmonellosis, may serve as the marker of a future
increase in resistance to fluoroquinolones, as has happened with
Escherichia coli [10].
In this work we studied the resistance patterns to nalidixic
